Abiraterone Acetate CAS:154229-18-2

Androgen antagonists.Abiraterone acetate (TABERNA, USAN, BAN, JAN) (notam nomina Zytiga, Abirate, Abretone, Abirapro) est steroidalis antiandrogen, specifically androgen synthesis inhibitor, usus est in re cum metastatic castratio repugnans prostatae cancer (antea hormone repugnans vel prostatae cancer hormone-refractus) – i.e., prostatae cancer non respondet androgen privatio vel curatio cum androgen receptor antagonists. Est prodrug agenti agenti abiraterone, et venales sunt a Janssen Biotech sub commercio Zytiga. Praeter, Intas pharmaceutica medicamentum mercatus est sub nomine Abiratas, Cadila Pharmacum medicamentum Abretonianum mercatus est, and Glenmark Pharmaceuticals as Abirapro.

Aceta Abiraterone probata a Civitatibus Foederatis Americae Food et Drug administrationis die Aprilis 28, 2011. FDA emissio diurnaria referens ad tempus III clinicae probationis in qua usus abiraterone adiunctus est cum media superstes. 14.8 mensibus versus 10.9 menses cum placebo; studio omissus primo ob eventum.

Usus in Cancro Abiraterone acetate approbatur utendum cum cancer prostatae tractare quae metastasizavit (ad alias partes corporis). It is used in patients whose disease has not gotten better with other hormone therapy.Abiraterone is also being studied in the treatment of other types of cancer.